Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.

Literature DB >> 20585014

Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.

Dan M Roden, Alan R Shuldiner.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20585014 PMCID： PMC2921991 DOI： 10.1161/CIRCULATIONAHA.110.973362

Source DB: PubMed Journal: Circulation ISSN： 0009-7322 Impact factor: 29.690

× No keyword cloud information.

26 in total

1. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.

Authors: Shirley Murphy; Rosemary Roberts
Journal: J Allergy Clin Immunol Date: 2006-01 Impact factor: 10.793

2. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.

Authors: M Gilard; B Arnaud; G Le Gal; J F Abgrall; J Boschat
Journal: J Thromb Haemost Date: 2006-08-08 Impact factor: 5.824

3. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors: S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal: Lancet Date: 2002-03-02 Impact factor: 79.321

4. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors: Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal: Blood Date: 2006-06-13 Impact factor: 22.113

5. Identification of the platelet ADP receptor targeted by antithrombotic drugs.

Authors: G Hollopeter; H M Jantzen; D Vincent; G Li; L England; V Ramakrishnan; R B Yang; P Nurden; A Nurden; D Julius; P B Conley
Journal: Nature Date: 2001-01-11 Impact factor: 49.962

6. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.

Authors: D Sibbing; D Gebhard; W Koch; S Braun; J Stegherr; T Morath; N Von Beckerath; J Mehilli; A Schömig; T Schuster; A Kastrati
Journal: J Thromb Haemost Date: 2010-05-21 Impact factor: 5.824

7. Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245

Review 8. Platelet function monitoring in patients with coronary artery disease.

Authors: Paul A Gurbel; Richard C Becker; Kenneth G Mann; Steven R Steinhubl; Alan D Michelson
Journal: J Am Coll Cardiol Date: 2007-10-23 Impact factor: 24.094

9. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.

Authors: Paul A Gurbel; Kevin P Bliden; Bonnie L Hiatt; Christopher M O'Connor
Journal: Circulation Date: 2003-06-09 Impact factor: 29.690

10. HLA-B*5701 screening for hypersensitivity to abacavir.

Authors: Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow
Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245

10 in total

1. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Authors: S A Scott; S Martis; I Peter; Y Kasai; R Kornreich; R J Desnick
Journal: Pharmacogenomics J Date: 2011-03-01 Impact factor: 3.550

Review 2. Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Authors: Adam S Fisch; Christina G Perry; Sarah H Stephens; Richard B Horenstein; Alan R Shuldiner
Journal: Curr Cardiol Rep Date: 2013-07 Impact factor: 2.931

3. Platelet aggregation pathway.

Authors: Katrin Sangkuhl; Alan R Shuldiner; Teri E Klein; Russ B Altman
Journal: Pharmacogenet Genomics Date: 2011-08 Impact factor: 2.089

Review 4. Pharmacogenomics: the genetics of variable drug responses.

Authors: Dan M Roden; Russell A Wilke; Heyo K Kroemer; C Michael Stein
Journal: Circulation Date: 2011-04-19 Impact factor: 29.690

5. Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors: Craig R Lee; Vindhya B Sriramoju; Alexandra Cervantes; Lucius A Howell; Nicholas Varunok; Shivanshu Madan; Kasey Hamrick; Melissa J Polasek; John Andrew Lee; Megan Clarke; Jonathan D Cicci; Karen E Weck; George A Stouffer
Journal: Circ Genom Precis Med Date: 2018-04

10. Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele.

Authors: Wenwen Qian; Liang Chen; Lizhu Zhang; Mingzhu Gao; Chunxia Wang; Xi Qian; Chengjian Yang; Yahui Lin; Zhijun Han
Journal: J Thorac Dis Date: 2022-07 Impact factor: 3.005